The FDA has approved adrabetadex (Lembaz; Mandos, LLC) injection to reduce mortality risk in adult and pediatric patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and severe inherited disorder.The approval was based on survival rates in 36 patients treated with the drug in three clinical trials. Those receiving the drug had a 55% reduction in mortality risk, and a longer median survival time than matched control individuals.Median survival was 8.5 years among treated patients compared with 4.9 years in the control group. This survival benefit persisted regardless of concomitant treatment with miglustat (Zavesca), a substrate reduction therapy often used off-label for NPC in the US.“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” acting FDA commissioner Kyle Diamantas said in a news release.NPC is a rare lysosomal storage disorder that affects approximately 1 in 150,000 individuals. Patients with NPC are unable to properly process cholesterol and other intracellular lipids, leading to their accumulation and progressive neurologic deterioration.“Over time, these substances accumulate, particularly in the brain, causing progressive neurological decline, including loss of movement, coordination, and the ability to swallow,” the FDA noted in its release.Infantile-onset NPC is a severe form of the disease characterized by neurologic symptoms that present before age 6. Although two other treatments have previously been approved for NPC, neither has been associated with a reduction in mortality risk.Adrabetadex is approved for adult and pediatric patients with infantile-onset NPC who weigh at least 7 kg (nearly 15 lb). It is administered by intrathecal injection every 2 weeks by a trained healthcare provider.The most common adverse events associated with adrabetadex include hearing problems, balance and coordination difficulties, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.The drug also carries a boxed warning for hearing impairment, including permanent hearing loss. The FDA recommends comprehensive hearing evaluations before treatment initiation and regularly throughout treatment. Based on the results of this testing, dose adjustments may be necessary.Still, “today’s approval marks an important milestone,” said Diamantas.“For the first time, there is a treatment shown to help adults and children with this serious disease live longer,” he added.Adrabetadex is a proprietary mixture of 2-hydroxypropyl-beta-cyclodextrin isomers designed to address impaired intracellular cholesterol trafficking, according to the drug’s manufacturer, Beren Therapeutics. The drug received Breakthrough Therapy designation in December 2025.“For families who know how precious time can be, these encouraging survival findings carry profound meaning and hope for more time together,” Heather Moran-Teal, executive director of the National Niemann-Pick Disease Foundation, said in another release.“Lembaz represents an important step forward in the treatment of this devastating disease,” Moran-Teal added.The approval was granted to Mandos, LLC, a subsidiary of Beren Therapeutics.
FDA OKs First Drug to Reduce Mortality in Niemann-Pick C
Full Article
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.